This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-07. Anything still debated is marked as such rather than presented as settled.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Supercritical fluid extraction has been used in determining hydrocarbon components in water. Processes that use sCO2 to produce micro and nano scale particles, often for pharmaceutical uses, are under development. The gas antisolvent process, rapid expansion of supercritical solutions, and supercritical antisolvent precipitation (as well as several related methods) process a variety of substances into particles. Due to its ability to selectively dissolve organic compounds and assist enzyme functioning, sCO2 has been suggested as a potential solvent to support biological activity on Venus- or super-Earth-type planets.
== External links == Official website (in German) "Search results for 'Kermani'". Goethe-Institut (in German). 23 June 2021. Retrieved 25 September 2021. "German-Iranian author receives culture prize after religious row". DW.COM. 27 November 2009. Retrieved 25 September 2021.
Other uses include determining high-precision values for plutonium and uranium isotopes in a rapid fashion, investigating the atomic properties of technetium at the ultra trace level, and capturing the concurrent excitation of stable daughter atoms with the decay of their parent atoms as is the case for alpha particles, beta rays, and positrons. RIS is now in very common use in research facilities where the quick and quantitative determination of the elemental composition of materials is important. Pulsed laser light sources provide higher photon fluxes than continuous-wave lasers do, however the use of pulsed lasers currently limit vast applications of RIMS in two ways. One, photo ions are created only during short laser pulses, thus significantly reducing the duty cycle of pulsed resonance ionization mass spectrometers relative to their continuous-beam counterparts. Two, incessant drifts in laser pointing and pulse timing alongside jitters between pulses severely hamper chances of reproducibility. These issues affect the extent to which resonance ionization can be used to solve some of the challenges confronted by practical analysts today; even so, applications of RIMS are replete in various traditional and emerging disciplines such as cosmochemistry, medical research, environmental chemistry, geophysical sciences, nuclear physics, genome sequencing, and semiconductors.
Sources: en.wikipedia.org
== Scope == EARS-Net tracks resistance rates reported in routine clinical antimicrobial susceptibility data from local and clinical laboratories, gathered by national surveillance programs and laboratory networks. Resistance status is determined according to EUCAST guidelines. Only data from invasive isolates (blood and cerebrospinal fluid) are included in EARS-Net. The antibiotics for which resistance is tracked varies by species, and is based on EUCAST recommendations. Resistance data is collected for these eight pathogens only:
C(OH)-N that crosslinked its backbone amide groups, forming a two-dimensional fabric. Other primary structures of proteins were proposed by various researchers, such as the diketopiperazine model of Emil Abderhalden and the pyrrol/piperidine model of Troensegaard in 1942. Although never given much credence, these alternative models were finally disproved when Frederick Sanger successfully sequenced insulin and by the crystallographic determination of myoglobin and hemoglobin by Max Perutz and John Kendrew.
== References == Anderson, G.B., (1999). "Epidemiological features of chronic low back pain". The Lancet (1) 354 Langevin, H.M., Bouffard, N.A., Badger, G.J., Churchill, D.L., Howe, A.K., (2006). "Subcutaneous tissue fibroblasts cytoskeletal remodeling induced by acupuncture: evidence for a mechanotransduction-based mechanism". J Cell Physiol (3) 207 Langevin, H.M., Churchill, D.L., Cipolla, M.J., (2001). "Mechanical signalling through connective tissue: A mechanism for the therapeutic effect of acupuncture". FASEB J (1) 15
Post-infectious glomerulonephritis can occur after essentially any infection, but classically occurs after infection with the bacteria Streptococcus pyogenes. It typically occurs 1–4 weeks after a pharyngeal infection with this bacterium, and is likely to present with malaise, a slight fever, nausea and a mild nephritic syndrome of moderately increased blood pressure, gross haematuria, and smoky-brown urine. Circulating immune complexes that deposit in the glomeruli may lead to an inflammatory reaction. Diagnosis may be made on clinical findings or through antistreptolysin O antibodies found in the blood. A biopsy is seldom done, and the disease is likely to self-resolve in children in 1–4 weeks, with a poorer prognosis if adults are affected or if the affected children are obese.
Sources: en.wikipedia.org
Epithelial cells climb over one another in order to migrate. This growing sheet of epithelial cells is often called the epithelial tongue. The first cells to attach to the basement membrane form the stratum basale. These basal cells continue to migrate across the wound bed, and epithelial cells above them slide along as well. The more quickly this migration occurs, the less of a scar there will be. Fibrin, collagen, and fibronectin in the ECM may further signal cells to divide and migrate. Like fibroblasts, migrating keratinocytes use the fibronectin cross-linked with fibrin that was deposited in inflammation as an attachment site to crawl across.
== Discoidin domain receptors == Discoidin domain receptors form a subgroup of receptor tyrosine kinases. Receptor activation happens when collagen binds into preformed DDR dimers on cell membrane, when collagen is bound, a conformational change probably occurs, which causes cytosolic kinases to rotate to face each other, and their autophosphorylation. The exact way of receptor activation is unknown so far. Unlike other tyrosine-kinase receptors, maximal activation of receptors occurs 18 hours after collagen stimulation. They function as receptors for different collagen types, they recognize many fibrillar collagens and they are capable of binding some nonfibrillar collagens as well. Nevertheless, the native conformation of collagen is a requirement for receptor binding, denatured collagen is not bound. DDRs are expressed widely already during development and level of expression is high in adults as well. DDR1 is a homodimer. Its ectodomain consists of a collagen-binding discoidin domain followed by ~200 residues of unknown structure. It binds fibril-forming collagens and primarily type IV collagen, but also collagen of types I, VI, VIII. It is expressed mainly in epithelial cells and leukocytes and expression rate changes due to cell cycle phase. Functions include: mammary gland development; arterial wound repair; regulation of cell proliferation, cell adhesion and MMP expression; kidney function, differentiation and function of leukocytes. DDR2 structure as above. Binds fibril-forming collagens, collagen of types I, II, III and X.
An autosomal recessive encephalopathy associated with mutations in this gene has also been reported. Increased glomerular and mesangial deposition of collagen IV occurs in diabetic nephropathy and increased urinary levels are associated with the extent of renal injury.
Capacitive sensors were included throughout the inner structure of the Knuckles and hand tracking, whilst rudimentary during development, allowed for "five fingered hands". Gabe Newell, President of Valve, expressed excitement to Game Developer about being able to "build much more interesting kinds of experiences" and expand beyond the conventional keyboard and mouse. Approximately several hundred pairs of Knuckles controllers were later distributed to developers as part of a kit for testing purposes. Despite the small number of developers reviewing, some uploaded videos of their prototype testing to sites such as YouTube. One such review by Brian Lindenhof found some quirks with the hand tracking A patent from Valve was later matched to the Knuckle controllers, with extra features including force resistant sensors, which uses electrical resistance to resist applied force, expanding game development options. Tracking beacons for the controllers and headset were conceptualised and designed by Alan Yates, with the blueprints later shown at the 2016 Hackaday Supercon. Using infrared, multiple placed "beacons" can triangulate the location of the user and controllers, this was achieved with the use of a spinning mirror system bouncing IR into the surrounding area. Early challenges included finding a functional rotation speed of the mirror, and sourcing parts for mass production, instead of relying on eBay as they had up until that point. Early versions faced quality issues. Valve adopted the first revision, by this time known as Lighthouse Base Stations.
Shortcomings of the sequence database searching workflow Due to the complex nature of peptide fragmentation in a mass spectrometer, derivative fragmentation patterns fall short of reproducing experimental mass spectra, especially relative intensities among distinct fragments. Thus, sequence database searching faces a bottleneck of limited specificity. Sequence database searching also demands vast search space, which still could not cover all possibilities of peptide dynamics, exhibiting limited efficiency post-translational modifications). The search process is sometimes slow and requires costly high-performance computers. In addition, the nature of sequence database searching disconnects the research discoveries among different groups or at different times.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.